1
Tarran Jones
David M Hilbert, Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, Aeres Biomedical, Jones Day, November 9, 2010: US07829086 (17 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


2
Tarran Jones
Tarran Jones, David G Williams: Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Aeres Biomedical, Jones Day, March 5, 2013: US08389688

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework r ...


3
Hilbert David, Jones Tarran, Williams David G: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Medimmune, Aeres Biomedical, Hilbert David, Jones Tarran, Williams David G, CORUZZI Laura A, September 13, 2007: WO/2007/103470 (12 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework r ...


4
Jones Tarran, Williams David G: Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Aeres Biomedical, Jones Tarran, Williams David G, CORUZZI Laura A, September 13, 2007: WO/2007/103469 (9 worldwide citation)

The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework r ...


5
JONES TARRAN, WILLIAMS DAVID G: Anticorps humanisés anti CD22 et leur utilisation dans le traitement de loncologie, la transplantation et les maladies auto-immunes, Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen, Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. AERES BIOMEDICAL, January 2, 2013: EP2540741-A1

The present application provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framework ...


6
JONES TARRAN, WILLIAMS DAVID G: [fr] Anticorps humanisés anti CD22 et leur utilisation dans le traitement de loncologie, la transplantation et les maladies auto-immunes, [de] Humanisierte Anti-CD22-Antikörper und ihre Verwendung bei der Behandlung von Krebs, Transplantationen und Autoimmunerkrankungen, [en] Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. AERES BIOMEDICAL, October 16, 2013: EP2650306-A1

[en] The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region ('VH') and four human or humanized framew ...


7
Chestnut Robert W, Polley Margaret J, Paulson James C, Bayer Robert: Anticorps de la p-selectine et leur utilite, Antibodies to p-selectin and their uses. Cytel Corporation, Aeres Biomedical, FETHERSTONHAUGH & CO, November 11, 1993: CA2135083

The present invention relates to compositions and methods for treating inflammation and other pathological conditions us-ing novel blocking P-selectin antibodies which inhibit binding of an antibody secreted by a cell line designated ATCC Accession No. HB11041 to P-selectin as measured by a competit ...


8
Chestnut Robert W, Polley Margaret J, Paulson James C: Antibody against p-selectin and utilization thereof. Aeres Biomedical, February 16, 2006: JP2006-045234

PROBLEM TO BE SOLVED: To provide a new antibody against P-selectin associated with the inhibition of cell adhesion by using a new immunoglobulin reacting with a functional epitope on the P-selectin (CD62, granule membrane protein-140 (GMP-140)/platelet-activation-depending granule envelope (PADGEM)/ ...


9

10
Tarran Jones
Chesnut Robert W, Polley Margaret J, Paulson James C, Jones S Tarran, Saldanha Jose W, Bendig Mary M, Kriegler Michael, Perez Carl, Bayer Robert, Nunn Michael: Anticorps pour la p-selectine et leurs utilisations, Antibodies to p-selectin and their uses. Cytel Corporation, Aeres Biomedical, GOWLING LAFLEUR HENDERSON, November 10, 1994: CA2162149

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized anti ...